CBD and Autism

Peer-reviewed studies into the potential effects of Cannabidiol and Autism

On this page, CBD and Autism, you will find research pertaining to the use of Cannabidiol and Cannabinoids and its possible effects on Autism. The information below is not meant to influence your opinion, but rather give you access to a wealth of scientific literature in an attempt to make and educated and informed choice. Click Here to see all of the conditions that have been researched alongside CBD and Autism.

Endocannabinoid Signaling in Autism

From the abstract:

Autism spectrum disorder (ASD) is a complex behavioral condition with onset during early childhood and a lifelong course in the vast majority of cases. To date, no behavioral, genetic, brain imaging, or electrophysiological test can specifically validate a clinical diagnosis of ASD… Here we present a modern view of the eCB system, and alterations of its main components in human patients and animal models relevant to ASD. This review will thus provide a critical perspective necessary to explore the potential exploitation of distinct elements of eCB system as targets of innovative therapeutics against ASD.

Cannabinoid Receptor Type 2, but not Type 1, is Up-regulated in Peripheral Blood Mononuclear Cells of Children Affected by Autistic Disorders

From the abstract:

In this study, we investigated the involvement of cannabinoid system in [peripheral blood mononuclear cells] from autistic children compared to age-matched normal healthy developing controls… Our data indicate CB2 receptor as potential therapeutic target for the pharmacological management of the autism care.

A Novel Approach to the symptomatic Treatment of Autism.  By Lester Grinspoon M.D.

From the article:

Parents of some autistic children report that cannabis eases behavioral problems more effectively than conventional pharmaceuticals. Their anecdotal evidence should be taken seriously by medical researchers..

Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders.

From the abstract:

Autism spectrum disorders (ASDs) are heterogenous neurodevelopmental disorders characterized by impairment in social, communication skills and stereotype behaviors… Our data provides a basis for further studies in evaluating the role of the cannabinoid and monoaminergic systems in the etiology of ASDs.

Targeting the endocannabinoid system in the treatment of fragile X syndrome.

From the abstract:

The endocannabinoid system (ECS) is a key modulator of synaptic plasticity, cognitive performance, anxiety, nociception and seizure susceptibility, all of which are affected in FXS (fragile X syndrome, the mosto common monogenic cause of inherited intellectual disability and autism)… blockade of ECS is a potential therapeutic approach to normalize specific alterations in FXS.

Deficient adolescent social behavior following early-life inflammation is ameliorated by augmentation of anandamide signaling.

From the abstract:

Early-life inflammation has been shown to exert profound effects on brain development and behavior, including altered emotional behavior, stress responsivity and neurochemical/neuropeptide receptor expression and function… data suggest that alterations in eCB signaling following postnatal inflammation contribute to impairments in social behavior during adolescence and that inhibition of FAAH could be a novel target for disorders involving social deficits such as social anxiety disorders or autism.